Patient Care
The Byers Eye Institute at Stanford University is dedicated to combating blindness and preserving sight. We deliver effective, integrated vision care across all specialties at our state-of-the-art facilities as well as via phone or video.
Make an appointment today by
calling 650-723-6995.
Research
Our premier group of visionary scientists is leading innovations in diagnostics and the next generation of vision restorative therapeutics. Stanford's vision research faculty bring the latest in basic and translational research as well as clinical trials.
Education
Residency training and clinical and research fellowships at Stanford in every specialty as well as fellowships in international health and ophthalmic innovation, offer exciting opportunities to advance the field and develop careers.
Welcome
Jeffrey L. Goldberg, MD, PhD
Professor and Chair
Department of Ophthalmology
Welcome to the Byers Eye Institute in the Department of Ophthalmology at Stanford University School of Medicine, a top-tier, internationally recognized, multidisciplinary center combining world-class resources with a commitment to providing the highest level of diagnostic and therapeutic care to our patients.
Through an integrated, personalized approach to healthcare delivery, our dedicated team provides the latest therapies in treating eye disorders. Associated with Stanford Health Care, and the Lucille-Packard Children's Hospital, our faculty and staff provide excellence in ocular and vision healthcare to patients across Northern California and from around the world, while our cutting-edge team of researchers carries out some of the most innovative laboratory research and clinical trials anywhere.
Whether you are a patient, a resident, or a leader in academic or clinical ophthalmology, I invite you to explore our programs, visit our clinics and operating rooms, and receive your eye care from our premier faculty.
I am very proud of our exceptional faculty and staff and their accomplishments in our mission areas of patient care, research, education and community outreach.
We are here for you.
Read the Vision Matters Annual Report
Where Technology Meets the Eye
Ophthalmology has long been at the forefront of medical innovation, but the pace of those advances has only accelerated in recent years. Throughout this report, you'll see how our faculty are leading that momentum.
The theme of our 2025 Vision Matters annual report, Where Technology Meets the Eye, highlights some of the most exciting advances currently available in our clinics as well as the advances being made in our laboratories and via artificial intelligence that hold great promise to help us reach our goal of eradicating blindness and preserving sight.
Recent News
-
Stanford Medicine scientists, Dr. Yang Sun and Dr. Zhiquan Liu, developed an ultrasmall and versatile gene activator, TIGRa, that is easier to deliver into the body. In mice, they used it to prevent blindness from retinal injury.
-
Stanford's Daniel Palanker Honored for Vision-Restoring Retinal Implant
Following a nomination by the Air Force Office of Scientific Research, the Defense Health Agency awarded the Outstanding Research Accomplishment (Individual/Academia) award to Palanker.
-
The secret to scaling AI in brain research may be in the data rather than the models
A Stanford-led team developed a powerful new AI model called OmniMouse, which shows improving brain datasets may be more important than increasing model size.
-
Research shines new light on how our brains interpret the world
For decades, neuroscientists have understood the visual cortex to function much like a sketch artist, breaking down the world into simple, well-defined edges—such as the borders where light meets shadow—before higher-level brain regions integrate these into complex representations.
-
Silicon Chips on the Brain
Fabricated as a single chip, the new implant is orders of magnitude faster and smaller than today’s state-of-the-art brain-computer interfaces, offering an opportunity for more efficacious treatment of a number of neurological conditions…
-
Eye prosthesis is the first to restore sight lost to macular degeneration
In a Stanford Medicine-led clinical trial of a wireless retinal prosthesis, people with advanced macular degeneration regained enough vision to read books and subway signs.
-
 copy.jpg)
First FDA-approved MacTel treatment available at the Byers Eye Institute
The Byers Eye Institute is proud to offer the only FDA-approved treatment for patients diagnosed with macular telangiectasia type 2, known as MacTel. Make an appointment at: 650.723.6995. No center has implanted more of these devices in patients.
From the Annual Report
-
Tracking childhood vision
Gayathri Srinivasan, OD, MS, clinical associate professor at the Byers Eye Institute, has been steadfast in her mission and passion to identify and treat underprivileged children with vision disorders for over 15 years.
-
Meet our Newest Faculty 2025
Growing our impact through the Spencer Center for Translational Research and at the Byers Eye Institute, we are always seeking and recruiting the best talent from around the world to expand our research, clinical care, studies and trials, collaborations, and more. Over the past year, we've welcomed six new full-time faculty who will enhance the work our clinicians and scientists have been diligently pushing forward for decades to preserve sight and eradicate blindness.
-
Dr. Sophia Wang builds tools to transform glaucoma care with personalized treatment planning
Glaucoma is a collection of eye diseases that damage the optic nerve — the critical connection between the eye and brain — and is a leading cause of irreversible blindness. It can affect people of all ages, though it is most common among those over the age of 60. Known as the “silent thief of sight,” it affects around 4.22 million people in the United States, but researchers estimate that only half of those people know they have the disease.
-
Why Give 2025
Recent breakthroughs in neuroscience, genetics, imaging, stem cell medicine, computer science and engineering have given us real opportunity to cure these as-yet incurable diseases and to reverse the vision loss they cause.
